The prognostic value of Tau expression in tumor tissue has been suggested in several studies [26], including one performed in 54 patients treated with paclitaxel and cisplatin as first-line chemotherapy for locally-advanced or metastatic breast cancer [27]. The gene discussed is MAPT; the disease is neoplasm.